Lytix Biopharma is committed to serve unmet patient needs and aspire to continuously strengthen the position of its drug candidates by establishing long-term strategic and value creating collaborations within the pharma industry, and with clinical and academic institutions.

Lytix is focused on immuno-oncology and has valuable experience from almost 20 years in in situ vaccination and oncolytic therapies. Throughout these years Lytix has provided flexible partnership structures to its partners.

Lytix Biopharma is looking for, and open to, collaborations and partnerships for the two leading molecules:

  • LTX-315; targeting solid tumors accessible for direct and intradermal injections, among them: basal cell and squamous cell carcinoma, melanoma, head and neck cancer and breast cancer
  • LTX-401; targeting high unmet need in solid tumors with deep seated lesions, in particular liver- and colorectal cancer. 


Lytix welcomes business proposals related to exploring our therapies in combination with other immuno-oncology therapies with distinct separate mode of actions that could work in synergy with our in situ vaccination technology.

To get in touch with Lytix regarding possible collaboration and partnership, please send an e-mail to

Verrica Pharmaceuticals Inc.
Verrica is a Nasdaq-listed dermatology therapeutics company developing medications for skin diseases requiring medical interventions and is headquartered in West Chester, Pennsylvania. In August 2020, Lytix announced that it entered into a license agreement providing Verrica Pharmaceuticals with a world-wide license to develop and commercialize LTX-315 for all malignant and pre-malignant dermatological indications (skin cancer). Lytix maintains all rights to the use of LTX-315 in patients with metastatic melanoma and metastatic Merkel cell carcinoma. Verrica will assume responsibility for manufacturing of the LTX-315 drug product, while Lytix retains responsibility for manufacturing of the active pharmaceutical ingredient (API). Under the license agreement, Lytix may receive aggregate payments of more than USD 111m as signing fee and upon achievements of certain clinical, regulatory and sales milestones as well as tiered royalty payments in the double-digit teens.

Verrica intends to focus initially on basal cell and squamous cell carcinoma as the lead indications for development for LTX-315. The American Cancer Society has estimated that about 5.4 million basal cell carcinoma (BCC) and squamous cell carcinomas (SCC) are diagnosed in the US annually. With about 80% of these skin cancers being BCC there is a significant potential for new treatment options


Aurelius Biotherapeutics LLC
In March 2021, Lytix announced it had entered into a strategic partnership with Aurelius Biotherapeutics whereas Aurelius will investigate and develop LTX-122 for the veterinary medicine market. The partnership is arranged with an option period where Aurelius has initiated further feasibility studies on LTX-122 together with their own technology, which is based on adoptive T-cell transfer to treat dog lymphoma.